Tag
biotech
5 articles
Argenx's Vyvgart Franchise Offers 23% Upside; Four Studies Coming
The biotech reported 60% year-over-year revenue growth in Q2 2026 on gMG and CIDP therapies, with Wall Street's consensus target at $1,180.25.
Revolution Medicines' Rasonque Wins FDA Nod in Pancreatic Cancer
Daraxonrasib cleared 6.5 months early with Phase 3 data showing median 13.2-month survival versus 6.7 months on chemotherapy in second-line metastatic pancreatic cancer.
Moderna Stock Drops 25% on Cancer Vaccine Success—Wall Street's Skepticism Shows Risk
Investors sold despite positive melanoma vaccine trial results, pointing to lingering doubts about Moderna's ability to execute beyond COVID and generate sustainable returns.
Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.
Self-Driving Labs Lift Consumables Demand, Split Fortunes Between Commodity and Scarce Inputs
AI-powered labs are expanding total experiment volume, pressuring commodity labware suppliers while strengthening the market position of scarce reagents and specialized inputs.